Cui et al. (2010) found that down-regulation of ABI1 expression plays an important role in tumor progression in gastric carcinoma, and it may be a potential diagnostic biomarker and a promising target for medical treatment. Besides, (Nath et al., 2019) found that ABI1 could suppress EMT of tumor through inhibiting downstream of non-canonical WNT signaling (FYN-STAT3 pathway) and the loss of ABI1 would drive the tumorigenesis of prostate tumors. The gene discussed is STAT3; the disease is gastric carcinoma.